Home
Breast & breast cancer
Breast cancer Benign breast lesions Prophylactic mastectomy
Breast reconstruction
All techniques Implant reconstruction Latissimus dorsi flap DIEP flap (abdomen) Gracilis flap (thigh) Fat grafting (lipofilling) Flat closure Intimate surgery
Benign gynaecological surgery
Uterus Ovaries and tubes Cervix Vulva and vagina
Gynaecological cancers
Cervical cancer Ovarian cancer Uterine cancer Vulvar cancer Borderline tumours Articles About
Request a callback Book on Doctolib →
In the consulting room, Dr Jérémie Zeitoun, in a white coat, smiles at a patient of about 50 seated across the desk, who smiles back.
Breast

Lobular carcinoma in situ (LCIS): surgery or surveillance?

Your breast biopsy report mentions “lobular carcinoma in situ (LCIS)”. The word “carcinoma” is frightening. In its classic form, however, lobular carcinoma in situ is not a cancer, it is a high-risk lesion. When the biopsy shows it, it is most often operated on; surveillance is the exception. This article explains what lobular carcinoma in situ is, why it is most often operated on, in which cases surveillance remains possible, and why there is no reason to remove the breast.

Dr Jérémie Zeitoun
In brief

Classic lobular carcinoma in situ is a high-risk lesion, not a cancer: it raises the risk of breast cancer 8- to 10-fold. Surgery is most often performed; surveillance remains the exception. A preventive mastectomy is not indicated, except in rare cases. Dr Jérémie Zeitoun explains how the course of action is decided.

This article is drawn in particular from the SENORIF 2025-2026 guidelines.

Dr Jérémie Zeitoun hands a report to a patient of about 45, seated opposite him across the desk.

Does your biopsy report mention lobular carcinoma in situ?

Bring it with your images: Dr Jérémie Zeitoun, breast cancer surgeon, reviews the file and tells you whether to operate or to monitor, with the reason for that choice.

HIGH-RISK LESION

High-risk lesion, not a cancer: what that means

The lobule, where the lesion arises

The breast contains ducts, which carry the milk, and lobules, the small glands that produce it. Each lobule is made up of tiny cavities, the acini.

In lobular carcinoma in situ, abnormal cells, which no longer adhere to one another, fill and distend these acini. “In situ” means “in place”: the cells stay inside the lobule and have not invaded the surrounding tissue.

Classic lobular carcinoma in situ is therefore not a breast cancer. It is one of the high-risk lesions of the breast, also called “B3 lesions” or “borderline lesions”, because they are neither entirely benign nor a cancer.

It does not necessarily turn into a cancer: it signals a higher risk of breast cancer, in either breast.

It is most often discovered by chance, when exploring microcalcifications, the small calcium deposits seen on the mammogram (see breast microcalcifications). It accounts for 0.5 to 4% of biopsies of benign breast lesions, according to the 2022 recommendations of the French National College of Gynaecologists and Obstetricians.

AFTER THE BIOPSY

After the biopsy: why surgery is most often performed

Breast ultrasound: a radiologist, probe in hand, examines the breast of a patient of about 50, lying down and covered with a sheet.

What the biopsy does not always show

The biopsy samples a fragment of the suspicious area, not the whole area. Next to the lesion, there may be a cancer that the sample did not reach: this is underestimation.

That is why, when the biopsy shows lobular carcinoma in situ, surgery is most often performed: analysis of the area removed makes it possible to be sure that there is no cancer next to it.

For the classic form, with no other associated lesion and when the images match the biopsy result, the proportion of cancers discovered at surgery is low: less than 5% according to the 2023 European guidelines on B3 lesions, 0 to 4% according to the American Society of Breast Surgeons. It rises markedly for the pleomorphic and florid forms: according to American series, often from a single centre, 25 to 60% for the pleomorphic form and 30 to 40% for the florid form.

These figures are orders of magnitude, not your personal risk.

The check after every biopsy

After every biopsy, whatever the result, we check that the result matches what the images show: this is radiological-pathological concordance (radiological for the imaging, pathological for the examination under the microscope). This check is systematic. In the event of discordance, new samples or surgery are offered: see discordance between imaging and biopsy.

The radiologist takes a sample under ultrasound guidance from the breast of a patient lying down under sterile drapes.

Core needle biopsy or vacuum-assisted biopsy

The core needle biopsy takes fine cores with a needle. The vacuum-assisted biopsy, performed by the radiologist under image guidance, takes more tissue and can sometimes remove the whole visible area (see breast biopsy). According to the guidelines, for the classic form:

  • diagnosis on core needle biopsy: a vacuum-assisted excision is offered to remove the area;
  • diagnosis on vacuum-assisted biopsy: surgical excision in the event of discordance or if a lesion remains visible on the images; otherwise, follow-up by imaging is possible, under the conditions described below. Most often, Dr Zeitoun operates.

For the pleomorphic and florid forms, management is that of ductal carcinoma in situ: surgical excision.

The biopsy, the ultrasound and the mammogram are performed by the radiologist, who then refers you to Dr Zeitoun with the reports (see mammogram, breast ultrasound and breast magnetic resonance imaging (MRI)).

THE OPERATION

If an operation is proposed

In the radiology room, the radiologist prepares the marking of the area to be removed in a calm patient of about 55, covered with a sheet.

Excision of a lesion that cannot be felt

Lobular carcinoma in situ generally cannot be felt. The radiologist therefore places a hookwire before the procedure: a fine metal wire, placed under local anaesthesia on the morning of the operation or the day before, which shows the surgeon where to operate (see preoperative localisation).

The marked area is then removed by a conservative excision (see lumpectomy): the breast is preserved. The specimen is X-rayed during the procedure to check that the lesion has indeed been removed.

The excision is done as day surgery, at Clinique Hartmann: you go home the same day. See surgery for high-risk lesions of the breast, preparing for your operation and postoperative recovery.

The margins and the report

The specimen removed is analysed under the microscope. The margins are the edges of the specimen: we look at whether abnormal cells touch them.

  • Classic form: if the margins are involved, there is no re-excision. It is not a cancer but a high-risk lesion: a further operation is not recommended. There is no additional treatment. Surveillance of both breasts is enough.
  • Pleomorphic or florid form: if the margins are involved, a further excision is recommended.

Analysis of the specimen can also reveal a cancer that the biopsy had not seen, which then changes the management. See understanding your pathology report and margins and re-excision after lumpectomy.

Radiotherapy

Radiotherapy is a treatment with rays, delivered to the breast after the operation. For the classic form, treated by conservative surgery, there is no indication for radiotherapy: no additional treatment is necessary. Radiotherapy is indicated only for the pleomorphic forms or forms with necrosis, as necrosis can accompany the florid form as well as the pleomorphic form.

MASTECTOMY

Why there is no mastectomy

Lobular carcinoma in situ does not justify removing the breast. The French guidelines state: “no indication for prophylactic mastectomy” for lobular carcinoma in situ.

Those of the French National College of Gynaecologists and Obstetricians of 2022 point the same way: in the absence of a demonstrated benefit on survival and quality of life, it is not recommended to perform a risk-reducing mastectomy for a high-risk lesion of the breast (strong recommendation).

For the classic form, it is a high-risk lesion, not a cancer: the answer is regular surveillance of both breasts, and not removal.

The rare exception

The French National College of Gynaecologists and Obstetricians of 2022 provides for a single exception, a weak recommendation: pleomorphic or florid lobular carcinomas in situ, multicentric or diffuse, associated with complex imaging or other risk factors, in a young woman (under 40). In this case, the file is discussed in a multidisciplinary team meeting.

Preventive surgery can also be discussed in other situations, such as a BRCA1 or BRCA2 gene mutation, always in a multidisciplinary team meeting. See preventive mastectomy, bilateral preventive mastectomy, reconstruction after preventive mastectomy and preventive surgery in the case of BRCA.

Dr Jérémie Zeitoun hands an appointment card to a smiling patient of about 55, a folder on the desk in front of her.

Would you like a second opinion before deciding?

Excision, surveillance or a simple question about your report: Dr Zeitoun reviews your reports and your images, and tells you what he would do in your place, with no obligation.

Frequently asked questions

Is lobular carcinoma in situ (LCIS) a cancer?

In its classic form, no: it is a high-risk lesion, not a cancer. The cells stay in the lobules and the lesion mainly signals a higher risk of breast cancer in both breasts. The pleomorphic and florid forms are closer to a cancer: they are managed like ductal carcinoma in situ.

Should lobular carcinoma in situ always be operated on?

No, but most often yes: when the biopsy shows lobular carcinoma in situ, it is most often operated on. For the pleomorphic and florid forms, surgical excision is the course of action, after a multidisciplinary team meeting. For the classic form, surveillance is the exception: it is possible only under precise conditions, and is decided case by case in a multidisciplinary team meeting and with you.

What does “radiological-pathological concordance” mean?

After every biopsy, we check that the biopsy result matches what the images show: radiological for the imaging, pathological for the examination under the microscope. This check is systematic. In the event of discordance, new samples or surgery are offered. See discordance between imaging and biopsy.

The margins are not clear: is a second operation needed?

For the classic form, no: there is no re-excision, because it is not a cancer but a high-risk lesion, and no additional treatment is necessary. For the pleomorphic and florid forms, a further excision is recommended. See margins and re-excision after lumpectomy.

Is radiotherapy needed after the operation?

Not for the classic form: no additional treatment is necessary. It is indicated only for the pleomorphic forms or forms with necrosis. See radiotherapy.

Can lobular carcinoma in situ affect the other breast?

Yes. The classic form often affects several areas of the same breast and, in 30 to 67% of cases, both breasts. That is why surveillance covers both breasts.

How does surveillance work, and is an MRI needed?

Clinical examination every year, two-view mammogram every year for 10 years, then every 2 years. Magnetic resonance imaging (MRI) is not systematic. See mammogram.

Is mastectomy recommended?

No, as a rule. The French guidelines do not provide for preventive mastectomy for lobular carcinoma in situ. The only exception, a weak recommendation, concerns a multicentric or diffuse pleomorphic or florid form, with complex imaging or other risk factors, in a woman under 40. See preventive mastectomy.

Is the operation done as day surgery?

Yes. The hookwire is placed on the morning of the procedure or the day before, the excision takes place at Clinique Hartmann and you go home the same day. See postoperative recovery.

What are Dr Zeitoun’s fees?

Dr Zeitoun practises in Sector 2 (non-OPTAM) and charges fees above the French Social Security rate for all consultations and procedures. Most international patients are not covered by French Social Security. A detailed quote is given during the consultation, before any procedure. If you are covered, the Assurance Maladie reimburses on the basis of the Social Security rate, and your health insurance may cover all or part of the additional fees, depending on your policy. See quote, stay and cover.

Further reading

Other high-risk breast lesions and images to explore.

FREN
ONLINE CONSULTATIONVideo consultation · by appointment